Dublin listed medical device company, Mainstay Medical, has reported that all implants for its ReActiv8 trial for US commercialisation have been completed.
ReActiv8 is a device Mainstay is developing to treat chronic lower back pain.
The trial involves a total of 204 patients. The company says it remains on track to announce full data towards the end of the year.
Mainstay recently raised €30 million through the placement of new shares to fund completion of the study.
In results for the six months to the end of June, the company reported revenue of $0.4 million.
Operating expenses were $15.8 million, primarily driven by costs relating to the trial and associated commercialisation efforts.
"We remain on track to meet our target of having 10 or more physician partners performing multiple implants by the end of this year," Jason Hannon, CEO of Mainstay said.
"We believe this momentum will set us up for more meaningful commercial expansion in 2019 as more customers begin to adopt and get comfortable with selecting the appropriate patients for the therapy."